Introduction {#s1}
============

Microbial infection of a corneal transplant is a complication that is a bane to all corneal surgeons, the sequelae of which can be devastating. Although infrequent, in the early postoperative period, keratitis after keratoplasty may threaten corneal graft clarity and result in severe vision loss and, in worst cases, may cause endophthalmitis with potential need for enucleation.

During the last two decades, lamellar keratoplasty (LK), in the forms of anterior lamellar keratoplasty (ALK) and endothelial keratoplasty (EK), has largely supplanted penetrating keratoplasty (PK) for selective replacement of the diseased corneal stroma or damaged endothelium.[@R1] Advantages of these techniques are reduced risk of allograft rejection, shorter postoperative steroid treatment, early removal of sutures, no 'open-sky' surgery and preservation of globe integrity.[@R2] All these benefits contribute to the reduced risk of early and late complications occurring after LK when compared with PK. Common feature to all LK procedures is the formation of a surface of contact between the donor graft and the recipient bed, namely, graft--host interface.[@R3] Infection arising at this anatomical level represents a rare peculiar complication that may develop after all forms of LK. Diagnosis and treatment of this type of keratitis is a challenge for the surgeon due to the sequestered location of the infection in the deep stroma, with impaired access for microbiological testing and penetration of antimicrobial drugs. For these reasons, diagnosis of the infectious agent may be delayed or remain presumptive and treatment is often initiated empirically.

Cases of corneal interface infection after both anterior and posterior lamellar keratoplasty are reported in the literature. Due to its infrequent occurrence, knowledge of this new form of infection is limited and treatment strategies as well as clinical outcomes widely vary according to different authors.

The purpose of this review is to describe the clinical features of interface infectious keratitis (IIK) occurring after ALK and EK and to analyse the treatment outcomes in order to establish a rationale for therapy.

Method of literature search {#s2}
===========================

We searched PubMed database (1949--2018) and Ovid Medline (1946--2018) for peer-reviewed publications relevant to the topic of corneal interface infection following lamellar keratoplasty. Key words included: keratitis, corneal interface infection, deep anterior lamellar keratoplasty (DALK), endothelial keratoplasty (EK), Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK). We did not use any date or language restrictions in the electronic searches. Articles in all languages were considered, provided that the non-English articles included English abstracts. The last electronic search was made on June 2018. Data on patients anagraphic, keratoplasty procedure, time to onset of infection, microorganism isolates, therapy and visual acuity were compiled using Microsoft Excel software V.15.25 (Microsoft, Redmond, Washington, USA) and summarised using SPSS software V.20 for Microsoft Windows.

Results {#s3}
=======

The literature search retrieved 122 titles and abstracts in English or with English translations. All papers available were reviewed by two authors (LF and EM) to check for adherence to the topic interface infection following lamellar keratoplasty. We selected 18 single case reports and eight case series of patients who developed infection originating at the graft--host interface after anterior or posterior LK. Cases where onset of infection did not originate in the graft--host interface were omitted. Single cases, part of case series, not referable to IIK were excluded from the analysis (ie, Tsui *et al* [@R4] cases 1, 2, 3, 4, 5, 8, 9).

Patient characteristics and clinical outcomes of all cases included in this review are reported separately in [tables 1 and 2](#T1 T2){ref-type="table"} according to the type of surgery: DALK and EK. In the latter group, we included patients who underwent either DSAEK or DMEK.

###### 

Literature review of clinical cases and case series of interface keratitis following DALK

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Patients (n)   Age\             Microorganism isolated from specimens    Time to infection onset (day)   Donor rim culture                 Time to positive donor rim culture report (day)   Medical treatment topical and /or systemic                                          Surgical treatment                                                                Endophtha\   Visual outcome\   Postoperative complications
                                                 (years)                                                                                                                                                                                                                                                                                                                                             lmitis       (BSCVA Snellen)   
  ------------------------------- -------------- ---------------- ---------------------------------------- ------------------------------- --------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------ ----------------- -----------------------------
  Panda *et al* [@R5]             1              55               *Rhodotorula* sp\                        5                               nr                                nr                                                Topical natamycin 5% Amphotericin B 0.15%                                           Donor button exchange                                                             No           nr                No
                                                                  (donor button+interface biopsy)                                                                                                                                                                                                                                                                                                                                   

  Fontana *et al* [@R6]           1              30               *Candida albicans*\                      28                              *C. albicans*                     5                                                 Topical amphotericin B (3 mg/mL)\                                                   Donor button exchange+interface amphotericin B (5 µg/0.1 mL)\                     No           20/25             No
                                                                  (donor button)                                                                                                                                               Liposomal amphotericin B (3 mg/kg) IV                                               PK                                                                                                               

  Kanavi *et al* [@R7]            2              21               *Candida* *glabrata*\                    60                              nr                                nr                                                Topical amphotericin B,\                                                            Interface irrigation with DM rupture\                                             No           nr                No
                                                                  (donor button)                                                                                                                                               oral ketoconazole 400 mg once in a day                                              PK                                                                                                               

                                  25             *C. albicans*\   75                                       nr                              nr                                Natamycin 5%,\                                    PK                                                                                  No                                                                                nr           No                
                                                 (donor button)                                                                                                              oral ketaconazole 400 mg once in a day                                                                                                                                                                                                                 

  Zarei-Ghanavati *et al* [@R8]   1              35               *Klebsiella pneumoniae*\                 2                               *Klebsiella pneumoniae*           2                                                 Topical vancomycin (50 mg/mL), ceftazidime (50 mg/mL)                               PK                                                                                No           20/20             No
                                                                  (donor button)                                                                                                                                                                                                                                                                                                                                                    

  Caretti *et al* [@R9]           1              21               Actinomyces species\                     6                               nr                                nr                                                Topical ofloxacin 0.3%, betamethasone 0.13%+chloramphenicol 0.25%, amphotericin B   PK\                                                                               No           20/25             No
                                                                  (donor button)                                                                                                                                                                                                                                   PK graft exchange                                                                                                

  Bahadir *et al* [@R10]          1              23               Candida species\                         30                              Not performed                     na                                                Topical amphotericin B (5 µg/mL), cefuroxime (1 mg/mL)\                             Interface irrigation DM rupture\                                                  No           nr                No
                                                                  (donor button)                                                                                                                                               Liposomal amphotericin B (3 mg/mL) IV\                                              PK                                                                                                               
                                                                                                                                                                                                                               Oral itraconazole 200 mg OD                                                                                                                                                                          

  Sedaghat*et al* [@R11]          1              18               *C. albicans*\                           120                             Negative                          nr                                                Topical ceftazidime (50 mg/mL), vancomycin (50 mg/mL), natamycin 5%                 Interface irrigation (amphotericin B 0.15%) DM rupture                            No           20/30             No
                                                                  (irrigation liquid)                                                                                                                                                                                                                                                                                                                                               

  Wesse *et al* [@R12]            1              39               *Candida orthopsilosis* (donor button)   5                               Yeasts                            6                                                 Topical voriconazole, oral voriconazole 400 mg two times a day                      Interface irrigation voriconazole (0.25 mg/mL)+amphotericin B (0.5 mg/mL)\        No           20/630            No
                                                                                                                                                                                                                                                                                                                   PK                                                                                                               

  Murthy *et al* [@R13]           1              26               Atypical Mycobacterium\                  90                              nr                                nr                                                Topical amikacin 2.5%                                                               Donor button exchange\                                                            No           20/40             No
                                                                  (donor button)                                                                                                                                                                                                                                   PK                                                                                                               

  Le *et al* [@R14]               1              31               *C. glabrata*\                           6                               Medium culture negative\          nr                                                Topical levofloxacin 0.5%, fluconazole 0.5%                                         Interface irrigation cefuroxime 5%+fluconazole (0.8 g/L) donor button exchange\   No           20/40             No
                                                                  (donor button)                                                           Donor rim culture not performed                                                                                                                                         PK                                                                                                               

  Kodavoor[@R15]                  1              32N              Negative                                 90                              nr                                nr                                                Topical voriconazole, natamycin, oral itraconazole 100 mg twice a day               None                                                                              No           20/80             Leucomatous scar
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BSCVA, best-spectacle corrected visual acuity; DM, Descemet membrane; PK, penetrating keratoplasty; na, not applicable; nr, not reported.

###### 

Literature review of clinical cases and case series of interface keratitisfollowing DSAEK and DMEK

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 Patients (n)              Age (years)   Type of surgery                 Donor preparation                        Microorganism isolated from specimens      Time to infection onset (days)     Donor rim culture                          Time to positive donor rim culture report (days)                                            Medical treatment topical and /or systemic                                                                       Surgical treatment                                                                             Endophtha\              Visual outcome (BSCVA Snellen)   Postoperative complications
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       lmitis                                                   
  ------------------------------ ------------------------- ------------- ------------------------------- ---------------------------------------- ------------------------------------------ ---------------------------------- ------------------------------------------ ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------- -------------------------------- ------------------------------
  Koenig *et al*\                1                         80            DSAEK                           Uncut                                    *Candida albicans*\                        7                                  *C. albicans*                              5                                                                                           None                                                                                                             Donor lenticule removal then PK                                                                No                      NPL                              Phtisis bulbi\
  [@R16]                                                                                                                                          (donor lenticule)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Enucleation

  Kitzmann\                      2                         80            DSAEK                           nr                                       *C.* *albicans*\                           39                                 *C.* *albicans*,\                          3                                                                                           Topical amphotericin B 0.15%\                                                                                    Donor lenticule exchange+intracameral amphotericin B (5 µg/0.1mL)                              No                      20/50                            No
  *et al* ^[@R17]^                                                                                                                                (aqueous tap)                                                                 *Candida* *glabrata*, *Streptoco* *ccus*                                                                                               Oral fluconazole 200 mg two times a day                                                                                                                                                                                                                                  

                                 80                        DSAEK         nr                              *C.* *albicans*\                         41                                         *C.* *albicans*,\                  3                                          Topical amphotericin B 0.15%\                                                               Intracameral amphotericin B (5 µg/0.1 mL)×2\                                                                     No                                                                                             20/40                   No                               
                                                                                                         (anterior corneal infiltrate scraping)                                              *C.* *glabrata*, *Streptococcus*                                              Oral\                                                                                       Intravitreal amphotericin B (10 µg/0.1 mL)\                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                           fluconazole 200 mg two times a day                                                          Peripheral patch graft                                                                                                                                                                                                                                                   

  Chew *et al* [@R18]            1                         72            DSAEK                           Uncut                                    *C. parapsilosis*\                         2                                  Negative                                   na                                                                                          Topical amphotericin B (1 mg/mL)\                                                                                Intravitreal amphotericin B (0.1 mg)×3\                                                        Yes                     20/40                            No
                                                                                                                                                  (aqueous and vitreous tap)                                                                                                                                                                                           Oral voriconazole 200 two times a day                                                                            PK+vitrectomy                                                                                                                                           

  Lee *et* *al* ^[@R19]^         2                         81            DSAEK                           Precut                                   *C.* *glabrata*\                           30                                 *C.* *glabrata*                            3                                                                                           Topical amphotericin B 0.15%\                                                                                    PK+intravitreal amphotericin B (10 µg/0.1 mL)                                                  No                      20/25                            No
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                    Oral voriconazole 100 two times a day                                                                                                                                                                                                                                    

                                                           76            DSAEK                           Uncut                                    *C.* *albicans*\                           21                                 Negative                                   7                                                                                           Topical amphotericin B 0.15%\                                                                                    PK                                                                                             No                      NPL                              Supra choroidal haemorrhage\
                                                                                                                                                  (corneal scraping)                                                                                                                                                                                                   Oral fluconazole 200 mg two times a day                                                                                                                                                                                                                                  Phtisis bulbi

  Ortiz-Gomariz *et al* [@R20]   1                         76            DSAEK                           Uncut                                    *C. albicans*\                             90                                 Not tested                                 na                                                                                          Voriconazole 200 mg two times a day intravenous\                                                                 Donor lenticule removal+vitrectomy\                                                            Yes                     20/200                           No
                                                                                                                                                  (donor lenticule, aqueous+vitreous taps)                                                                                                                                                                             Topical voriconazole                                                                                             PK+trabeculectomy                                                                                                                                       

  Sharma *et al* [@R21]          1                         62            DSAEK                           nr                                       *Aspergillus fumigatus*\                   30                                 Negative                                   na                                                                                          Natamycin 5%\                                                                                                    PK                                                                                             No                      20/40                            No
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                    Voriconazole 200 mg two times a day                                                                                                                                                                                                                                      

  Yamazoe *et al* [@R22]         1                         74            DSAEK                           nr                                       *C. albicans*\                             34                                 *C. albicans*                              nr                                                                                          Topical voriconazole 1%+micafungin 0.1%\                                                                         Donor lenticule removal+posterior stroma debridement;\                                         No                      20/22                            No
                                                                                                                                                  (aqueous tap)                                                                                                                                                                                                        Intravenous voriconazole 200 mg two times a day                                                                  4 months later\                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        PK+gonioplasty+intraocular lens exchange                                                                                                                

  Holz *et* *al* ^[@R23]^        2                         69            DSAEK                           Precut                                   *C.* *albicans*\                           7                                  *C.* *albicans*                            nr                                                                                          Topical amphotericin B+voriconazole\                                                                             Donor lenticule removal\                                                                       No                      20/30                            No
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                    Oral fluconazole 200 mg two times a day                                                                          Intracameral amphotericin B (5 mg)+vancomycin (1 mg)+ceftazidime (2.2 mg)\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        PK+glaucoma tube                                                                                                                                        

                                 54                        DSAEK         Precut                          *C.* *albicans*\                         49                                         *C.* *albicans*                    nr                                         Topical amphotericin B (2 mg/mL)+voriconazole 1%. Oral fluconazole 200 mg two times a day   Intravitreal amphotericin B (5 µg/0.1 mL)×4\                                                                     No                                                                                             20/80\                  No                               
                                                                                                         (donor lenticule)                                                                                                                                                                                                                                             Lenticule removal\                                                                                                                                                                                              (previous RD surgery)                                    
                                                                                                                                                                                                                                                                                                                                                                       PK                                                                                                                                                                                                                                                                       

  Tu\                            2                         66            DSAEK                           nr                                       Not assessed                               90                                 Negative                                   na                                                                                          Oral fluconazole 200\                                                                                            Several intrastromal\                                                                          No                      20/500                           Corneal oedema
  *et al* ^[@R24]^                                                                                                                                                                                                                                                                                                                                                     mg two times a day                                                                                               amphotericin B (5 µg/mL)                                                                                                                                

                                 70                        DSAEK         nr                              Not assessed                             49                                         Negative                           na                                         Oral voriconazole\                                                                          Intrastiomal voriconazole\                                                                                       No                                                                                             20/60                   No                               
                                                                                                                                                                                                                                                                           100 mg BD                                                                                   (50 mg/mL) weekly for\                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                       3 weeks                                                                                                                                                                                                                                                                  

  Nahum\                         7                         52            DSAEK\                          Uncut for all\                           *Candida*\                                 112                                Negative for all\                          na for all\                                                                                 Same treatment for\                                                                                                                                                                                                                     20/20                            No
  *et al* ^[@R25]^                                                       for all\                        cases                                    *parapsilosis*                                                                cases                                      cases                                                                                       all patients.\                                                                                                                                                                                                                                                           
                                                                         cases                                                                                                                                                                                                                                                                                         Topical fortified\                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       antibiotics and antifungals.                                                                                                                                                                                                                                             

  83                             *Staphylococcus*\         56                                            20/100                                   No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                 *aureus*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  67                                                       21                                            20/100                                   No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  70                             *Candida parapsilosis*\                                                 20/200                                   No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                 (donor lenticule)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  63                             Nocardia species          28            Same procedure for all\         Not for all\                             20/50                                      No                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                         patients.\                      cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                         PK+intracameral amphotericin\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                         B, amikacin, vancomycin,\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                         ceftazidime                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                 *Staphylococcus*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  63                             *C. albicans*\                          No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                 (donor lenticule)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  71                             *Staphylococcus*          28            No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                           112                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Weng *et al* [@R26]            1                         80            DSAEK                           nr                                       *C. glabrata*\                             28                                 *Candida glabrata*                         6                                                                                           Topical amphotericin B 0.15%, vancomycin (50 mg/mL), tobramycin (14 mg/mL). Oral fluconazole 200 mg once a day   Lenticule removal+pars plana vitrectomy+intravitreal amphotericin B, vancomycin, ceftazidime   Yes                     20/200                           Corneal oedema
                                                                                                                                                  (donor lenticule and vitreous tap)                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Hsu *et al* [@R27]             1                         45            DSAEK                           nr                                       *C. albicans*\                             1                                  *C.* *albicans*                            nr                                                                                          Topical voriconazole 1%\                                                                                         Donor lenticule removal+intravitreal voriconazole 100 µg\                                      Yes                     20/100                           No
                                                                                                                                                  (aqueous tap, donor lenticule)                                                                                                                                                                                       Oral fluconazole 200 mg two times a day                                                                          PK+pars plana vitrectomy\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Repeat vitrectomy+glaucoma tube                                                                                                                         

  Villarubia *et al* [@R28]      1                         73            DSAEK                           Uncut                                    *C. albicans*\                             10                                 *C.* *albicans*                            10                                                                                          Topical voriconazole 1%\                                                                                         Intracameral voriconazole 0.15\                                                                No                      HM                               Optic atrophy
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                    Oral voriconazole 200 mg once a day                                                                              PK+intracameral and intravitreal voriconazole 0.1%\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Repeat PK+pars plana vitrectomy+glaucoma valve                                                                                                          

  Tsui *et a*l^[@R4]^            2                         85            DSAEK                           Precut                                   *C. albicans*\                             20                                 *C. albicans*                              1                                                                                           Topical amphotericin\                                                                                            Multiple intracameral\                                                                         No                      20/40                            No
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                    B 0.15%                                                                                                          amphotericin B 5 µg/0.1 mL                                                                                                                              

                                 75                                      Precut                          *C. albicans*\                           20                                         *C. glabrata*                      1                                          Oral fluconazole\                                                                           Donor lenticule\                                                                                                 No                                                                                             20/40                   No                               
                                                                                                         (donor lenticule)                                                                                                                                                 200 mg once a day                                                                           exchange PK                                                                                                                                                                                                                                                              

  Wilde *et al* [@R29]           1                         57            DSAEK                           Uncut                                    *Scopulariopsis gracilis* species          2                                  *S. gracilis* species                      2                                                                                           Topical amphotericin B 0.15%\                                                                                    Donor lenticule removal+multiple amphotericin B 5 µg/0.1 mL\                                   No                      20/40                            No
                                                                                                                                                                                                                                                                                                                                                                       Topical voriconazole 1%\                                                                                         PK                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                       Oral voriconazole 200 mg two times a day                                                                                                                                                                                                                                 

  Thompson *et al* [@R30]        1                         75            DMEK                            Prestripped                              *C. glabrata*\                             8                                  *C. albicans*                              2                                                                                           Topical voriconazole 1% Oral voriconazole 100 mg two times a day                                                 Intracameral and intravitreal voriconazole 100 µg\                                             No                      20/60                            No
                                                                                                                                                  (donor lenticule)                                                                                                                                                                                                                                                                                                                     Donor lenticule removal\                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        DSAEK                                                                                                                                                   

  Tu *et al* [@R31]              1                         61            DMEK                            nr                                       Not assessed                               30                                 *C. glabrata*                              14                                                                                          Oral fluconazole 200 mg two times a day                                                                          Two intrastromal amphotericin B 5 µg/0.1 mL                                                    No                      20/25                            No

  Porter*et al* [@R32]           1                         68            DSAEK                           nr                                       *Enterococcus faecalis*                    120                                Not tested                                 na                                                                                          Topical moxifloxacin 1%                                                                                          PK\                                                                                            Yes                     20/50                            No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Pars plana vitrectomy                                                                                                                                   

  Palioura\                      2                         81            DSAEK                           Precut                                   *C. albicans*\                             28                                 *C. albicans*                              7                                                                                           Topical amphotericin\                                                                                            Intracameral and                                                                               No                      20/30                            No
  *et al* ^[@R33]^                                                                                                                                (aqueous tap\                                                                                                                                                                                                        B (5) mg/mL+                                                                                                                                                                                                                                                             
                                                                                                                                                  donor lenticule)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                 67                        DSAEK         Precut                          *C. albicans*\                           42                                         Negative                           na                                         Voriconazole (10 mg/mL                                                                                                                                                                                       No                                                                                             20/20                   No                               
                                                                                                         (aqueous tap)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BSCVA, best spectacle corrected visual acuity; DSAEK, Descemet stripping automated endothelial keratoplasty; DMEK, Descemet membrane endothelial keratoplasty; PK, penetrating keratoplasty; HM, hand movement; NPL, no perception of light; RD, retinal detachment; na, not applicable; nr, not reported.

Deep anterior lamellar keratoplasty {#s3-1}
-----------------------------------

Twelve cases (11 case reports)[@R5] of IIK, developed after DALK, are reported in the literature since 1999 ([table 1](#T1){ref-type="table"}). The causative microorganism was *Candida* spp in seven cases (63%) and *Klebsiella pneumoniae, Rhodotolura* spp, *Actinomyces* spp and *Mycobacterium* spp in four cases. Infectious organisms were identified from cultures of the excised donor buttons in 10 cases and from the liquid employed to rinse the graft--host interface in one case. Donor rim cultures, obtained in five cases, resulted negative in two cases and positive in three cases, with correspondence to the organisms identified in the recipients. Culture results were available 5--7 days after surgery.

The median time to development of clinical infection, calculated for all patients, was 29 days (range 2--120 days). Infection was managed initially with topical and systemic antifungals in combination with antibiotics. The choice of a specific drug was made on the available information resulting from donor rim and/or excised donor button cultures. None except one patient[@R15] responded to medical treatment alone and 9 out of 12 patients required excisional PK with removal of the infected donor button and the host Descemet membrane (DM). One case was successfully treated by simply replacing the donor button, while preserving the intact host DM.[@R5] Irrigation of the donor--host interface with and without antifungals, attempted in six cases, resulted successful in only one case[@R11] and caused DM rupture in three cases. None of the patients developed endophthalmitis and no recurrence of infection was observed during follow-up. Median best spectacle corrected visual acuity (BSCVA) at 4--6 months follow-up was 20/30 (range 20/630--20/20).

Endothelial keratoplasty {#s3-2}
------------------------

Thirty-one cases (17 case reports)[@R16] of IIK, developed after EK, are reported in the literature since 2009 ([table 2](#T2){ref-type="table"}). Twenty-nine of them occurred after DSAEK and two after DMEK. Infectious microorganisms were identified in 28 patients from cultures of the explanted donor lenticules (15 cases) or from aqueous and vitreous taps (13 cases). The remaining three cases were diagnosed and treated empirically as fungal infection on the basis of their clinical appearance.[@R24] *Candida* spp was isolated in 21 specimens (75%) and *Aspergillus fumigatus* in one case, while bacteria in the form of *Staphylococcus aureus* (two cases), *Staphylococcus epidermidis* (one case), *Enterococcus faecalis* (one case) and *Nocardia* spp (one case) were identified in the remaining patients. Donor rim cultures, obtained in 28 cases, resulted negative in 13 cases and positive for *Candida* spp in the other 15 cases. Correspondence between the infectious microorganisms isolated from specimens and the ones cultured from positive donor rim was found in all patients.

The median time to development of clinical infection, in these patients, was 28 days (range 1--120 days). Rim cultures results became available after a median time of 5.5 days (range 3--14 days) after surgery.

Despite combined topical and systemic antifungals, medical treatment alone was unsuccessful in halting the progression of the infection in all except one case.[@R17] Surgical intervention by means of lenticule removal, intracameral and/or intravitreal antifungals injections and eventually PK was required to eradicate the infection in the majority of patients. In three cases, regression of infection was obtained with multiple intrastromal injections of amphotericin B (5 mg/mL) or voriconazole (50 mg/mL) inoculated closest possible to the graft--host interface, causing temporary focal graft detachment.[@R24]

Of all patients, five (16%) developed endophthalmitis and required pars plana vitrectomy and three (9%) developed surgical postoperative complications with severe sight loss. Median BSCVA measured 4--12 months after resolution of infection was 20/40 (range 20/500--20/20).

Discussion {#s4}
==========

IIK represents a subset of infectious keratitis originating at the graft--host interface and occurring exclusively after LK procedures. A recent report of the Eye Bank Association of America[@R34] encompassing 4 years (2017--2010) of activity, reported a cumulated frequency of postkeratoplasty infection of 0.026% for fungal and bacterial agents together, with a higher rate of fungal isolates (63%). The frequency of fungal infections after LK was nearly the double than PK, being 0.023% and 0.012%, respectively. The rate of fungal infection after anterior lamellar keratoplasty was 0.052% and 0.022% after EK. According to this report, there might be an increasing trend of occurrence of postkeratoplasty fungal infection since the introduction of EK as the procedure of choice for the treatment of corneal endothelial failure. A single-centre review of 1088 consecutive DSAEK surgeries, over an 8 years time lapse, reported 10 (0.92%) cases of interface infection, seven of them with culture positive results.[@R25] We should consider that the overall perception of an increased risk of fungal infection after EK may be the consequence of over-reporting a novel complication occurring after a new surgical procedure. Due to the lack of a physiological hypothesis, whether IIK may represent a significant threat after LK remains is yet to be defined.

Tissue manipulation either in the eye bank or in the operating room does not seem to influence the postoperative risk of bacterial or fungal infection.[@R34] In our review, postoperative interface keratitis occurred using tissues for EK prepared either by surgeons in the operating room (13 cases) or by eye bank technicians (eight cases). Correlation between recipient and donor rim isolates was found for most of the tissues prepared in eye banks, indicating the donor and not the processing as the source of infection. In this respect, Brothers *et al* [@R36] demonstrated that tissue warming during EK processing is responsible for promoting *Candida* growth in donor rims, advocating antifungal drug supplementation of storage media. Ritterband *et al* [@R37] proved the efficacy of added voriconazole to Optisol GS on reducing the rate of positive rim cultures. Organ culture is the preferred method of cornea preservation in Europe. With this storage method, prolonged storage time allows to conduct routine microbiology tests and to identify and discard contaminated corneas before they are issued for transplantation.[@R38] To date, lack of strong evidence of effectiveness of antifungals in storage media kept at hypothermic temperature (2°C−8°C), along with doubts regarding safety for the corneal endothelial cells, are presently not advising the addition of antifungals to cold storage media.[@R34]

Microorganisms involved in the development of IIK are more commonly fungi, in the form of *Candida* spp and less frequently bacteria ([tables 1 and 2](#T1 T2){ref-type="table"}). In both cases, the source of infection is primarily the donor cornea, with a high correspondence between the organisms isolated from the corneoscleral rims and the ones identified in the recipients postoperatively.[@R4] Regardless of the type of lamellar keratoplasty, early signs of infection may be noticed in the form of deep stromal infiltrates developing on average 1 month after surgery ([tables 1 and 2](#T1 T2){ref-type="table"}). Onset of infection may occur as early as few days[@R27] and up to 3 months[@R11] after surgery, depending on the pathogenicity, microbial load and virulence of the infectious agent. A high index of suspicion is required to diagnose IIK, as it often presents with minimal inflammatory signs and symptoms. At onset, slight ocular pain and redness may be the only symptoms reported by patients, while visual acuity may be unaffected. At slit lamp examination, the cornea is usually clear, single or multiple whitish infiltrates, ranging from less than 0.5--2 mm in diameter,[@R13] located at the graft--host interface, are the only visible signs of infection ([figure 1](#F1){ref-type="fig"}). The anterior chamber is usually quiet with no inflammation. Anterior segment optic coherence tomography is helpful to confirm the location of the infiltrates at the graft--host interface ([figure 2](#F2){ref-type="fig"}),[@R39] but does not offer diagnostic hints of the causative agent.[@R14] [@R31] In vivo confocal microscopy can be useful in cases where *Candida* spp infection is suspected by detecting hyperreflective round budding-like structures with a granular appearance, measuring 2--4 µm, with the absence of hyphae-like structures.[@R7] Nonetheless, the sensitivity and specificity of this examination are highly dependent on operator experience,[@R39] and its diagnostic capability is yet to be confirmed in the setting of IIK.

![*Candida glabrata* interface infection developed after Descemet membrane endothelial keratoplasty. (A) Slit-lamp photography showing multiple white infiltrates within the graft--host interface 28 days after surgery. (B) A high magnification view at the slit lamp.](bjophthalmol-2018-312938f01){#F1}

![*Candida glabrata* interface infection. Optical coherence tomography showing infiltrates placed anterior to the Descemet membrane within the area of the Descemet membrane endothelial keratoplasty graft.](bjophthalmol-2018-312938f02){#F2}

Worsening of the infection is characterised by coalescence of the infiltrates that increase in size and assume less-defined margins, with oedema and infiltration of the overlaying stroma. The anterior chamber may show reaction with cells and seldomly hypopyon ([figure 3](#F3){ref-type="fig"}). At this point, ocular pain and photophobia are markedly increased and visual acuity is reduced from previous visits. Hsu *e* *t al* [@R27] reported a case of *Candida albicans* interface infection after DSAEK rapidly developing corneal perforation and endophthalmitis few days after surgery.

![*Candida glabrata* interface infection developed after Descemet membrane endothelial keratoplasty. Slit-lamp photography showing worsening of the infection with infiltrates enlargement displaying a fluffy appearance.](bjophthalmol-2018-312938f03){#F3}

Due to the initial asymptomatic clinical picture and the similarity to epithelial ingrowth, IIK diagnosis and treatment are often postponed until symptoms and signs of spreading of the infection become evident. Early warning of a possible risk of infection may come from donor rim cultures that can address identification and drug sensitivities of the potential infectious microorganism within few days after surgery. This information is particularly useful in the event of an interface infection due to inherent difficulty to obtain microbiological samples, without surgical intervention and to the high correspondence between microorganisms isolated from recipient specimens and the ones cultured from donor rims ([tables 1 and 2](#T1 T2){ref-type="table"}). This may hold true particularly when donor rims are infected by *Candida species* [@R4] where the risk of contamination of the donor mate cornea has also to be taken into account.[@R17] In our literature review, positive donor rim cultures were highly predictive of the infectious agents isolated from recipients, not only for the majority of fungal but also for the minority of bacterial isolates. *Candida* species was the isolate most commonly involved in the development of interface keratitis after both DALK and EK (DSAEK and DMEK), suggesting a possible predisposition of this microorganisms for growing in a sequestered hypoxic environment, protected from the host immune system response.

Therapeutic algorithms for IIK are not yet defined. Conventional approach to the diagnosis and treatment of microbial keratitis is not applicable to IIK due to the deep stromal location of the infiltrates that precludes access for scrapings and cultures and impedes topical drug penetrations. Kitzman *et al* [@R17] described a case of IIK after DSAEK, caused by *C. albicans*, with an unusual extension to the corneal surface, allowing for scraping and cultures, that was successfully treated with topical antimicrobials. On the basis of the clinical appearance and of the available information (donor rim culture), treatment is usually started empirically with broad spectrum antimicrobial drops including antifungals (amphotericin B 0.15% or voriconazole 1%) and, in cases of highly suspected or proved fungal infection, with systemic antifungals (oral voriconazole 100--200 mg two times a day or oral fluconazole 200 mg two times a day). In our literature review, topical and systemic treatments were not successful alone on halting the progression of fungal and bacterial infection in the majority of DALK and EK cases, probably due to the difficulty to reach a therapeutic concentration at the site of infection. In order to provide maximum drug load exactly at the graft--host interface, irrigation of the DM after DALK and injection of antifungal drugs in the deep stroma after EK have been attempted with the aim of salvaging the graft and avoiding PK. Treatment was efficacious in some cases[@R24] but carries a risk of DM rupture (DALK)[@R7] or graft dislocation (EK) with a potential hazard for anterior chamber contamination. Furthermore, interface scarring may result after treatment limiting the visual outcome.[@R24]

Surgical intervention by donor graft removal was carried out in several cases with the dual purpose of reducing the microbial load and provide ample material for microbiology in order to address postoperative treatment. Disadvantage of this procedure is the risk of disseminating the infection into the anterior chamber and causing endophthalmitis. For this reason, donor lenticule removal was often followed by multiple intracameral and/or intravitreal injection of antifungals with a possible risk of toxicity for the intraocular structures. In our review, five patients (16%) with IIK after EK developed endophthalmitis requiring combined PK and pars plana vitrectomy. Among these, three were initially treated by donor lenticule removal.[@R20] To the contrary, none of the patients with IIK after DALK developed endophthalmitis, but donor graft exchange, attempted in three cases, was successful only in one.[@R5] Collected data suggests that in DALK, the host DM is temporary capable to withhold the infection and avoid dissemination, explaining the better visual outcomes and the fewer complication recorded after excisional PK in patients with DALK compared with patients with EK.

Early excisional PK with removal of the sequestered infection may be advocated as a safe and effective measure to treat a post-LK infection of fungal origin. In a large series of IIK cases after DSAEK, Nahum *et al* [@R25] described the results of early excisional PK with intracameral antimicrobials injection at the end of surgery. None of these patients developed endophthalmitis and most patients retained good visual acuity and a long-term graft clarity. Because the procedure was conducted in relatively quiet eyes, postoperative complications (ie, recurrence of infection, graft failure, macular oedema, glaucoma), frequently developing after longstanding inflammation, were few.

In conclusion, any small whitish interface opacity occurring days to weeks after any kind of LK should be followed closely and considered infectious, especially in the setting of a positive rim culture. Whenever we suspect a IIK, fungal infection by *Candida* species, originating from the donor graft, has to be considered the most likely diagnosis. Donor rim cultures of the grafted cornea as well as the mate cornea should be traced with the help of the eye bank to gather clues of the possible infectious agent. Medical treatment with direct injection of antimicrobials in the graft--host interface can be attempted to spare further surgical intervention. In view of the endophthalmitis risk, early intervention with excisional PK should be considered whenever signs of spreading of the infection become evident despite treatment.
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